Edition:
United States

bluebird bio Inc (BLUE.O)

BLUE.O on Nasdaq

156.20USD
16 Aug 2018
Change (% chg)

$1.90 (+1.23%)
Prev Close
$154.30
Open
$154.95
Day's High
$156.75
Day's Low
$153.07
Volume
997,910
Avg. Vol
789,869
52-wk High
$236.17
52-wk Low
$90.75

Chart for

About

bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical... (more)

Overall

Beta: 1.85
Market Cap(Mil.): $8,470.30
Shares Outstanding(Mil.): 54.16
Dividend: --
Yield (%): --

Financials

  BLUE.O Industry Sector
P/E (TTM): -- 99.04 30.20
EPS (TTM): -7.18 -- --
ROI: -23.22 3.31 12.77
ROE: -26.43 2.31 14.92

BRIEF-FDA Grants Breakthrough Therapy Designation To Lenti-D For The Treatment Of Cerebral Adrenoleukodystrophy

* FDA GRANTS BREAKTHROUGH THERAPY DESIGNATION TO LENTI-D™ FOR THE TREATMENT OF CEREBRAL ADRENOLEUKODYSTROPHY

May 23 2018

Medigene in for up to $1.5 billion under broader pact with Bluebird Bio

FRANKFURT German biotech firm Medigene has secured a wider remit under a collaboration with U.S. peer Bluebird Bio on a technology that boosts the immune response to cancer, increasing the pool of potential milestone payments to $1.5 billion.

May 14 2018

UPDATE 1-Medigene in for up to $1.5 bln under broader pact with Bluebird Bio

* Shares up 8 pct (Adds shares, background on technology, analyst comment)

May 14 2018

Medigene broadens alliance on T-cell receptors with Bluebird Bio

FRANKFURT, May 14 German biotech firm Medigene has secured a wider remit under a collaboration with U.S. peer Bluebird Bio on technology that boosts the immune response to cancer, increasing the pool of potential milestone payments to $1.5 billion.

May 14 2018

BRIEF-Bluebird Bio Reports Qtrly Net Loss Per Share $2.31

* BLUEBIRD BIO REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS

May 02 2018

BRIEF-Bluebird Bio And Celgene Corporation To Co-Develop Anti-Bcma Car T Cell Therapy Bb2121 In The U.S.

* BLUEBIRD BIO AND CELGENE CORPORATION ENTER INTO AGREEMENT TO CO-DEVELOP AND CO-PROMOTE ANTI-BCMA CAR T CELL THERAPY BB2121 IN THE UNITED STATES

Mar 28 2018

BRIEF-Bluebird Bio Reports Q4 Loss Per Share $2.52‍​

* BLUEBIRD BIO REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS

Feb 21 2018

Earnings vs. Estimates